Sign In
Buy BDRX
$2.31
-0.180 (-7.23%)
At Close: Jul 13, 2026
Result of Annual General Meeting
04:30pm, Tuesday, 30'th Jun 2026
June 30, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of Annual General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clini
June 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Bi
Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
08:30am, Monday, 29'th Jun 2026
June 29, 2026 Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Compa
Postponement and Re-scheduling of Annual General Meeting
04:30pm, Wednesday, 17'th Jun 2026
June 17, 2026 Biodexa Pharmaceuticals PLC Postponement and Re-scheduling of Annual General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biophar
Biodexa issues letter to Shareholders
08:30am, Thursday, 14'th May 2026
May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or pre
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
08:30am, Thursday, 02'nd Apr 2026
April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage
Preliminary Results for the Year Ended 31 December 2025
05:00pm, Friday, 27'th Mar 2026
March 27, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2025 Biodexa Phar
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
08:30am, Monday, 23'rd Mar 2026
March 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical sta
Biodexa Pharmaceuticals (NASDAQ:BDRX) Shares Scheduled to Reverse Split on Monday, April 6th
01:14am, Saturday, 21'st Mar 2026
Shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ: BDRX) are set to reverse split on the morning of Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The num
ADR Ratio Change
05:00pm, Wednesday, 18'th Mar 2026
March 18, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pip
Financial Comparison: Biodexa Pharmaceuticals (NASDAQ:BDRX) versus Radiopharm Theranostics (NASDAQ:RADX)
02:08am, Monday, 16'th Mar 2026
Radiopharm Theranostics (NASDAQ: RADX - Get Free Report) and Biodexa Pharmaceuticals (NASDAQ: BDRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will
Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
08:30am, Monday, 09'th Mar 2026
March 9, 2026 Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX),
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
07:30am, Thursday, 19'th Feb 2026
MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 20
Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
08:30am, Wednesday, 04'th Feb 2026
February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update
04:58am, Wednesday, 14'th Jan 2026
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ: BDRX - Get Free Report) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totali
